Testosterone vs RAD-140: Mechanism Comparison

Hormone vs Experimental Drug: Fundamental Category Distinction

Testosterone: FDA-Approved Natural Hormone

Testosterone represents primary endogenous androgenic hormone produced by Leydig cells in testes with established physiological functions: muscle protein synthesis and maintenance; bone mineral density regulation; sexual function including libido and erectile capacity; mood and cognitive function; red blood cell production through erythropoietin stimulation; and fertility through spermatogenesis support. FDA approves multiple testosterone formulations for hypogonadism treatment with decades of clinical research establishing safety and efficacy profiles.

For a focused breakdown of how testosterone suppression works during both TRT and enhancement use, visit our Testosterone Suppression Basics, which explains HPG-axis shutdown and recovery fundamentals.

Clinical development timeline: extensive human trials documenting testosterone replacement therapy benefits across multiple organ systems; established dosing protocols for therapeutic and supraphysiological applications; comprehensive safety data including cardiovascular monitoring, hematocrit management, and prostate assessment; and regulated pharmaceutical manufacturing ensuring product quality and consistency.

RAD-140: Experimental SARM Without FDA Approval

RAD-140 (testolone) constitutes selective androgen receptor modulator developed by Radius Health 2010 as investigational compound for muscle wasting and breast cancer applications. Clinical development history: entered Phase 1 trial for androgen receptor-positive metastatic breast cancer (NCT03088527); never progressed beyond Phase 1 despite initiation; no published human efficacy trials for muscle building or performance enhancement; and never received FDA approval for any indication.

Current status: remains experimental compound with minimal human safety data; no established therapeutic protocols or dosing guidelines; unregulated manufacture and distribution through supplement market; unknown product quality, purity, or consistency; and FDA explicitly classifies as unapproved new drug illegal to market for human consumption.

The Critical Difference: Suppression Without Replacement

Testosterone Suppression Mechanism

Both testosterone and RAD-140 suppress endogenous testosterone production through hypothalamic-pituitary-gonadal axis negative feedback: exogenous androgen (testosterone) or androgen receptor agonist (RAD-140) signals adequate androgenic stimulation; hypothalamus reduces gonadotropin-releasing hormone secretion; pituitary decreases luteinizing hormone and follicle-stimulating hormone; and Leydig cells cease endogenous testosterone production creating hypogonadal state.

Why Testosterone Replacement Works

Exogenous testosterone administration provides: direct testosterone molecule replacing suppressed endogenous production; aromatization to estradiol maintaining physiological estrogen necessary for bone health, lipid metabolism, sexual function; systemic androgenic support for libido, mood, energy, motivation; and continuation of anabolic stimulus despite endogenous production cessation.

Result: hormonal homeostasis maintained through exogenous provision—suppression occurs but doesn’t create deficiency state because replacement testosterone supplies physiological requirements.

Why RAD-140 Solo Creates Hormonal Deficiency

RAD-140 administration produces: suppression of endogenous testosterone production through HPG axis; no testosterone molecule provision (RAD-140 is SARM, not hormone); resulting hypogonadal state with low to absent testosterone; minimal to no estradiol (no testosterone substrate for aromatization); and loss of systemic androgenic support despite continued androgen receptor activation in select tissues.

User Experience Documentation

Community consensus emphasizes functional consequences: “RAD-140 shuts you down and doesn’t give test. Test shuts you down and gives you test. Take RAD by itself you’ll have no muscle gain eventually because you will have zero estrogen, your cock won’t function, you’ll look like shit, no motivation for life and feel horrible.” Additional perspective: “Take 500mg of test you’ll get big as fuck feel amazing and have drive and vigor. SARMs are nothing compared to test.”

This creates fundamental limitation where RAD-140 cannot function as testosterone replacement—suppression without provision produces symptomatic hypogonadism despite continued androgen receptor agonism in select tissues.

Documented Hepatotoxicity: Multiple Published Cases

Clinical Case Reports Compilation

Published medical literature documents multiple RAD-140-associated cholestatic liver injury cases with consistent presentation pattern:

Hepatotoxicity Pattern and Mechanism

RAD-140-associated liver injury demonstrates: cholestatic pattern (elevated bilirubin, alkaline phosphatase, gamma-glutamyl transferase); onset typically 2-16 weeks after initiation; dose-dependent relationship suggested but not definitively established; reversibility with cessation documented in all published cases; and mechanism likely related to selective androgen receptor modulation in hepatic tissue despite “selective” marketing claims.

Clinical significance: case report notes hepatotoxicity “potentially resulting in acute liver failure” indicating serious adverse event potential requiring medical intervention and hospitalization in documented cases.

FDA Explicit Warning

FDA regulatory position based on accumulated adverse event reports: “Life-threatening reactions, including liver toxicity, have occurred in people taking products containing SARMs.” This represents official federal acknowledgment of serious hepatotoxicity risk associated with RAD-140 and related SARMs—not theoretical concern but documented clinical reality.

Testosterone Hepatotoxicity Comparison

Injectable testosterone formulations (enanthate, cypionate, propionate, undecanoate) demonstrate: minimal hepatotoxicity through intramuscular depot bypassing first-pass hepatic metabolism; no C-17 alpha-alkylation structural modification; rare liver enzyme elevation in clinical practice; and negligible serious hepatic adverse events in decades of widespread medical use.

Distinction: testosterone injectable represents negligible hepatotoxic risk while RAD-140 demonstrates documented serious liver injury cases requiring cessation and medical management.

Cardiovascular Damage: Myocarditis and Heart Failure Cases

Published Cardiac Adverse Events

Medical literature documents multiple RAD-140-associated cardiovascular complications including myocarditis and severe heart failure:

Cardiovascular Risk Severity

Polish case demonstrates extreme severity: 22-year-old with no prior cardiac history developing left ventricular ejection fraction 15% (normal 55-70%) representing severe systolic dysfunction; New York Heart Association Class III heart failure (marked limitation of physical activity); and 6-month RAD-140 exposure creating potentially life-threatening cardiomyopathy in otherwise healthy young adult.

Recovery timeline: LVEF improvement to 40% over 9 months indicates partial recovery but not complete normalization—suggesting potential for persistent cardiac dysfunction even after cessation.

FDA Cardiovascular Warning

FDA explicitly addresses cardiovascular risk: “SARMs also have potential to increase risk of heart attack and stroke.” This regulatory statement acknowledges acute cardiovascular events beyond chronic effects—myocarditis, heart failure, and thrombotic complications documented in SARM users including RAD-140 specifically.

Testosterone Cardiovascular Profile

Testosterone cardiovascular effects represent managed risk rather than acute damage: hematocrit elevation requiring monitoring and phlebotomy if exceeds 52-54%; lipid profile changes (HDL reduction, variable LDL effects) manageable through lifestyle and medication; blood pressure elevation in susceptible individuals requiring antihypertensive therapy; but no documented acute myocarditis or severe heart failure in young healthy users comparable to RAD-140 cases.

Critical distinction: testosterone cardiovascular risks represent chronic manageable factors requiring monitoring; RAD-140 demonstrates acute cardiac damage (myocarditis, severe heart failure) in young users representing different risk category entirely.

Selectivity Claim: Marketing vs Clinical Reality

The Theoretical Selectivity Premise

RAD-140 marketing emphasizes tissue selectivity: “Works selectively by only targeting muscle and bone cells, reducing harmful side effects. This means other organs in body are not affected.” Claimed mechanism: selective androgen receptor modulation provides anabolic stimulus to muscle and bone without affecting prostate, cardiovascular system, liver, or other organs—creating superior safety profile versus testosterone’s systemic effects.

Androgen Receptor Binding Affinity

Preclinical research documents RAD-140 androgen receptor affinity: Ki = 7 nM versus testosterone 29 nM and DHT 10 nM, indicating stronger receptor binding than testosterone. Additionally, claimed anabolic-to-androgenic ratio approximately 90:1 versus testosterone 100:100 baseline. These pharmacological properties support selectivity hypothesis from receptor binding perspective.

Clinical Reality Contradicts Selectivity Theory

Documented adverse events demonstrate non-selective organ effects:

Hepatic effects (directly contradicts selectivity): Multiple cholestatic liver injury cases documented; bilirubin peaks 38.5 mg/dL indicating severe hepatotoxicity; potential for acute liver failure per published case reports; and reversibility with cessation doesn’t negate serious hepatic impact.

Cardiovascular effects (directly contradicts selectivity): Acute myocarditis with severely elevated troponin; severe heart failure with LVEF 15% in young user; myopericarditis after single dose in adolescent; and FDA warning regarding heart attack and stroke risk.

Whole-organism effects: Mouse study documents “RAD140 increased frailty status and mortality risk in young and adult treated groups”; research conclusion: “Long-term RAD140 supplementation reduced indices of overall health and failed to improve strength in female mice, suggesting RAD140 may be more detrimental than beneficial.”

Selectivity Theory vs Evidence

Conclusion: “selectivity” represents marketing claim not supported by clinical evidence—documented serious adverse events in liver, heart, and overall health indicators directly contradict premise that RAD-140 “only affects muscle and bone” without harming other organs.

Regulatory Status and Official Warnings

FDA Classification and Enforcement

FDA explicitly classifies RAD-140 and related SARMs: “Unapproved drugs” that “cannot be legally marketed in U.S. as dietary supplement or drug at this time.” Enforcement actions include: multiple warning letters to manufacturers and distributors marketing SARMs; seizure of products containing RAD-140; and public health advisories warning consumers against SARM use.

FDA safety statement: “Life-threatening reactions, including liver toxicity, have occurred in people taking products containing SARMs. SARMs also have potential to increase risk of heart attack and stroke.” This represents federal regulatory acknowledgment of serious safety concerns based on adverse event accumulation.

International Regulatory Prohibitions

Testosterone Regulatory Status

Testosterone maintains: FDA approval for hypogonadism treatment (multiple formulations); Schedule III controlled substance classification (legal with prescription); decades of regulatory oversight establishing safety and efficacy standards; and pharmaceutical manufacturing ensuring product quality, purity, and consistency.

Legal access: testosterone available through legitimate medical channels with prescription; regulated dosing and monitoring protocols; and healthcare provider supervision ensuring appropriate use.

Muscle Building Evidence: Proven vs Unproven

Testosterone Established Efficacy

Decades of clinical research document testosterone muscle-building effects: dose-response relationship established across multiple studies; supraphysiological doses (300-600mg weekly) produce 3-6kg lean mass gains over 10-20 weeks; mechanisms well-characterized (protein synthesis, nitrogen retention, satellite cell activation); and predictable reproducible results in clinical and real-world applications.

RAD-140 Lack of Human Evidence

RAD-140 muscle-building efficacy in humans remains unproven: no published randomized controlled trials examining muscle growth outcomes; only Phase 1 safety trial in breast cancer patients (NCT03088527); preclinical rat data showing levator ani muscle weight increase comparable to testosterone in castrated animals; but animal models don’t reliably predict human efficacy.

Evidence gap: all muscle-building claims derive from: preclinical animal studies; anecdotal user reports; and theoretical extrapolation from androgen receptor binding affinity—none constituting rigorous human efficacy evidence.

Mouse Study Efficacy Failure

Research examining long-term RAD-140 effects documents: “Long-term RAD140 supplementation reduced indices of overall health and failed to improve strength in female mice, suggesting RAD140 may be more detrimental than beneficial.” This preclinical finding questions fundamental efficacy premise—if RAD-140 fails to improve strength and harms overall health in animal models, human efficacy becomes increasingly uncertain.

User Perspective on Comparative Efficacy

Community consensus favors testosterone: “Test blows SARMs out of water in terms of gains”; “Testosterone would be superior in every conceivable way”; and anecdotal reports describe RAD-140 as producing modest cosmetic changes without dramatic hypertrophy matching testosterone at equivalent suppression cost.

Can RAD-140 Replace Testosterone? Definitive Answer

Requirements for Testosterone Replacement

Effective testosterone replacement must provide: muscle anabolic stimulus; bone mineral density support; sexual function maintenance (libido, erectile function); mood and cognitive function support; energy and motivation; fertility preservation or support; estradiol provision through aromatization; and long-term safety with manageable risk profile.

RAD-140 Replacement Assessment

Expert Conclusion

Research explicitly addresses replacement question: “RAD-140 cannot replace testosterone. While it can mimic some of testosterone’s anabolic effects in muscle and bone, it lacks systemic influence needed to maintain health, vitality, and hormonal balance.” This conclusion reflects: suppression without replacement creating hormonal deficiency; lack of sexual function, mood, and energy support; absent estradiol provision; and insufficient safety data for long-term use.

Definitive answer: RAD-140 cannot replace testosterone for any purpose—therapeutic, performance, or otherwise. Fundamental limitation of suppression without hormonal provision makes RAD-140 unsuitable as testosterone alternative.

Complete Safety and Efficacy Profile Comparison

Key Takeaways: Testosterone vs RAD-140

• Category distinction fundamental—hormone vs experimental unapproved drug: Testosterone constitutes FDA-approved natural hormone with decades clinical research establishing efficacy and safety across multiple organ systems—muscle growth, bone density, sexual function, mood. RAD-140 represents experimental selective androgen receptor modulator never completing clinical development: single Phase 1 trial in breast cancer patients, no published human muscle-building studies, no FDA approval for any indication. Regulatory status: testosterone legal with prescription, RAD-140 classified unapproved new drug illegal to market. This category difference means not equivalent comparison—testosterone established medical therapy, RAD-140 investigational compound with unknown risk-benefit profile.
• Suppression without replacement creates RAD-140’s fundamental limitation: Both compounds suppress endogenous testosterone through HPG axis negative feedback. Critical difference: testosterone provides exogenous hormone replacement maintaining physiological function, RAD-140 offers no testosterone provision creating hormonal deficiency state. Consequence documented by users: “RAD-140 shuts you down and doesn’t give test resulting in zero estrogen, cock won’t function, look like shit, no motivation for life, feel horrible.” Research confirms: “RAD-140 cannot replace testosterone. While it can mimic some anabolic effects in muscle and bone, it lacks systemic influence needed to maintain health, vitality, and hormonal balance.” This limitation makes RAD-140 unsuitable as testosterone alternative for any purpose.
• Documented hepatotoxicity—multiple published cholestatic liver injury cases: Medical literature reports multiple RAD-140-associated liver injury: Leung 2022 (bilirubin 38.5 mg/dL after 5 weeks), Demangone 2024 (jaundice and hepatic steatosis 3 months), Perananthan 2024 (severe cholestatic injury “potentially resulting in acute liver failure”). Pattern: cholestasis with elevated bilirubin and alkaline phosphatase, onset 2-16 weeks typical, reversibility with cessation documented but serious intervention required. FDA explicit warning: “Life-threatening reactions, including liver toxicity, have occurred in people taking products containing SARMs.” Injectable testosterone demonstrates minimal hepatotoxicity bypassing first-pass metabolism—fundamental safety advantage where testosterone presents negligible hepatic risk versus RAD-140’s documented serious liver injury cases.
• Cardiovascular damage including myocarditis and severe heart failure: Published case reports document serious cardiac adverse events: Polish 2024 case (22-year-old severe heart failure, LVEF 15%, 6 months RAD-140), Padappayil 2022 (acute myocarditis, troponin 100.5 ng/mL), Schwartzman 2024 (myopericarditis after first dose, 16-year-old). FDA explicitly warns: “SARMs have potential to increase risk of heart attack and stroke.” Severity assessment: LVEF 15% represents life-threatening systolic dysfunction in previously-healthy young adult, partial recovery to 40% over 9 months indicates potential persistent impairment. Testosterone cardiovascular effects constitute chronic manageable factors (hematocrit, lipids, blood pressure) requiring monitoring—not acute cardiac damage events. Critical distinction: RAD-140 demonstrates acute myocarditis and severe heart failure representing different risk category entirely versus testosterone’s manageable cardiovascular factors.
• “Selectivity” marketing claim contradicted by documented organ damage: RAD-140 marketed emphasizing tissue selectivity: “works selectively by only targeting muscle and bone cells, other organs not affected.” Pharmacological support: androgen receptor affinity Ki = 7 nM versus testosterone 29 nM, claimed 90:1 anabolic-androgenic ratio. However, clinical reality contradicts selectivity theory: documented hepatotoxicity (cholestatic liver injury, potential acute liver failure), documented cardiovascular damage (myocarditis, severe heart failure), mouse study showing “increased frailty status and mortality risk,” research conclusion “reduced indices of overall health.” Selectivity represents theoretical receptor binding property not translating to organ-level safety—documented serious adverse events in liver, heart, and overall health directly contradict marketing claim that RAD-140 “only affects muscle and bone.”
• Regulatory prohibitions reflect accumulated safety concerns: FDA classifies RAD-140 as unapproved new drug illegal to market with explicit safety warning: “Life-threatening reactions including liver toxicity” and “potential to increase risk of heart attack and stroke.” Additional prohibitions: WADA (prohibited S1 anabolic agent), Department of Defense (prohibited all service members), Australia TGA (illegal without authority), proposed U.S. legislation (Schedule III controlled substance classification). This regulatory convergence reflects: documented serious adverse events, lack of approved therapeutic indication, unregulated manufacturing creating quality concerns, and insufficient safety data for human use. Testosterone maintains FDA approval for hypogonadism with regulated pharmaceutical manufacturing—legal access through medical channels versus RAD-140’s illegal marketing status.
• Muscle building efficacy unproven in humans versus testosterone’s established evidence: Testosterone efficacy documented through decades clinical research: dose-response relationship established, 3-6kg lean mass gains typical supraphysiological protocols, mechanisms well-characterized, predictable reproducible results. RAD-140 human efficacy remains unproven: no published randomized controlled trials examining muscle outcomes, only Phase 1 breast cancer safety trial exists, preclinical rat data shows comparable levator ani effects but animal models don’t predict human efficacy reliably. Mouse study questions fundamental efficacy: “failed to improve strength” and “reduced indices of overall health suggesting RAD140 may be more detrimental than beneficial.” User perspective: “Test blows SARMs out of water in terms of gains.” Evidence gap: RAD-140 claims derive from preclinical studies and anecdotal reports—not rigorous human efficacy data.
• RAD-140 cannot replace testosterone—definitive conclusion with evidence: Replacement requires: muscle anabolism (RAD-140 possibly, unproven humans), bone support (unknown), sexual function (RAD-140 no—suppresses without replacing), libido (no testosterone provision), mood/energy (no hormonal support), estradiol provision (no substrate for aromatization), long-term safety data (none available), FDA approval (unapproved illegal status). Research explicitly states: “RAD-140 cannot replace testosterone lacking systemic influence needed to maintain health, vitality, and hormonal balance.” Practical consequence: RAD-140 solo creates hormonal deficiency with sexual dysfunction, mood impairment, energy loss despite potential muscle effects. Fundamental limitation of suppression without replacement makes RAD-140 unsuitable as testosterone alternative for therapeutic, performance, or any purpose.

This page summarizes findings from sports physiology research, scientific literature and long-term community reports.

For another high-level comparison involving testosterone and a potent anabolic compound, see our Testosterone vs Trenbolone guide, which contrasts safety profiles, physiological effects, and real-world user outcomes.